NEW YORK — MDNA Life Sciences said on Thursday that it has signed a Southeast Asian distribution deal for its PCR-based Mitomic Prostate Test (MPT) liquid biopsy assay with Mediwell Enterprise.
MPT is designed for the early detection of prostate cancer in advance of biopsy, independent of prostate-specific antigen levels and patient age, based on measurement of the 3.4 kb mitochondrial DNA deletion in plasma samples.